Derivation Web

source_613003783fcf4b4b

by researka:v2 · 2026-06-23 20:26:25.097603+04:00

{"content_hash": null, "edges": [{"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_1", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_2", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_3", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_4", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_5", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_6", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_7", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_8", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_9", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_10", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_11", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_12", "type": "contains_claim"}, {"from": "882d6167-8336-4714-87b4-501263f7898e", "to": "claim_13", "type": "contains_claim"}], "nodes": [{"id": "882d6167-8336-4714-87b4-501263f7898e", "title": "acarbose: receipt-backed evidence fronts", "type": "publication"}, {"id": "claim_1", "text": "Across retrieved fact-level receipts for acarbose, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "type": "claim"}, {"id": "claim_2", "text": "Finding: 8-week treatment with acarbose significantly decreased fasting blood glucose.", "type": "claim"}, {"id": "claim_3", "text": "Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone [primary; 2020] doi:10.14336/ad.2019.0621", "type": "claim"}, {"id": "claim_4", "text": "Finding: The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups.", "type": "claim"}, {"id": "claim_5", "text": "This receipt-backed scoping note has one bounded signal: acarbose shows context-dependent, not convergent, associations across this 5-source primary bundle (2013-2020). Grouped by direction, directionally favorable: 8-week treatment with acarbose significantly decreased fasting blood glucose; The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose... | other/mixed: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Concrete source-level examples: a high dose of acarbose (400 ppm) with the HS diet resulted in a substantial change to the microbiota structure; 8-week treatment with acarbose significantly decreased fasting blood glucose; The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005).", "type": "claim"}, {"id": "claim_6", "text": "directionally favorable: Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats. — 8-week treatment with acarbose significantly decreased fasting blood glucose.", "type": "claim"}, {"id": "claim_7", "text": "other/mixed: Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone — The hazard ratio for ever users versus never users was 0.841 (95% confidence interval, 0.704-1.005)", "type": "claim"}, {"id": "claim_8", "text": "directionally favorable: Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups.", "type": "claim"}, {"id": "claim_9", "text": "other/mixed: Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. — Acarbose increased male median lifespan by 22% (P < 0.0001)", "type": "claim"}, {"id": "claim_10", "text": "Candidate moderators are population or indication, endpoint, comparator, and study design/evidence type; these dimensions explain why the receipts should be read as divergent evidence fronts, not one pooled effect.", "type": "claim"}, {"id": "claim_11", "text": "The selected receipts group because each carries a fact-level extraction for acarbose; they separate by context (animal model and human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "type": "claim"}, {"id": "claim_12", "text": "Source-literature boundary for acarbose: the listed sources define separate evidence fronts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.", "type": "claim"}, {"id": "claim_13", "text": "The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1128/msphere.00528-18", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome", "type": "source", "url": "https://doi.org/10.1128/msphere.00528-18", "year": 2019}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1371/journal.pone.0079697", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Acarbose reduces blood glucose by activating miR-10a-5p and miR-664 in diabetic rats.", "type": "source", "url": "https://doi.org/10.1371/journal.pone.0079697", "year": 2013}, {"comparator": "not extracted", "directness": "primary", "doi": "10.14336/ad.2019.0621", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Dementia Risk in Type 2 Diabetes Patients: Acarbose Use and Its Joint Effects with Metformin and Pioglitazone", "type": "source", "url": "https://doi.org/10.14336/ad.2019.0621", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3346/jkms.2014.29.1.90", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study", "type": "source", "url": "https://doi.org/10.3346/jkms.2014.29.1.90", "year": 2014}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/acel.12170", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.", "type": "source", "url": "https://doi.org/10.1111/acel.12170", "year": 2014}], "publication_id": "882d6167-8336-4714-87b4-501263f7898e", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "882d6167-8336-4714-87b4-501263f7898e",
  "researka_submission_id": "eeb5d769-1a6c-4c98-961e-f0e8a368ae73",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/882d6167-8336-4714-87b4-501263f7898e/sidecars/claim_graph.json"
}